Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort

Highlights

Adjuvant imatinib treatment was associated with a significant reduction in the early hazard of recurrence or death (HR, 0.19) in patients with KIT exon 9-mutant gastrointestinal stromal tumors (GISTs).

The study demonstrated a clear overall survival (OS) benefit (HR, 0.37) for patients receiving adjuvant imatinib compared to observation alone.